Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma), a tyrosine k...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gobin, Bérengère, Moriceau, Gatien, Ory, Benjamin, Charrier, Céline, Brion, Régis, Blanchard, Frederic, Redini, Françoise, Heymann, Dominique
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3944320/
https://ncbi.nlm.nih.gov/pubmed/24599309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0090795
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados